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Familial Hypercholesterolaemia is an autosomal, dominant genetic disorder that leads to elevated blood cholesterol
and a dramatically increased risk of atherosclerosis. It is perceived as a rare condition. However it affects 1 in 250 of
the population globally, making it an important public health concern. In communities with founder effects, higher
disease prevalences are observed.
We discuss the genetic basis of familial hypercholesterolaemia, examining the distribution of variants known to be
associated with the condition across the exons of the genes LDLR, ApoB, PCSK9 and LDLRAP1. We also discuss
screening programmes for familial hypercholesterolaemia and their cost-effectiveness. Diagnosis typically occurs
using one of the Dutch Lipid Clinic Network (DCLN), Simon Broome Register (SBR) or Make Early Diagnosis to
Prevent Early Death (MEDPED) criteria, each of which requires a different set of patient data. New cases can be
identified by screening the family members of an index case that has been identified as a result of referral to a lipid
clinic in a process called cascade screening. Alternatively, universal screening may be used whereby a population is
systematically screened.
It is currently significantly more cost effective to identify familial hypercholesterolaemia cases through cascade
screening than universal screening. However, the cost of sequencing patient DNA has fallen dramatically in recent
years and if the rate of progress continues, this may change.
Keywords: Familial hypercholesterolaemia, FH, cascade screening, screening, cholesterol, universal screening,
atherosclerosis, CVD, CHDBackground
Familial Hypercholesterolaemia (FH, OMIM #143890) is
a common genetic cause of premature Coronary Heart
Disease (CHD). It is an autosomal, dominant, inherited
disorder of lipoprotein metabolism that results in a
raised Low Density Lipoprotein Cholesterol (LDL-C)
plasma concentration.
Heterozygous FH (HeFH) is the most common
monogenic disorder, affecting 1 in 200–250, twice as
high as previously thought [1], with a penetrance of
greater than 90 % [2]. It is believed that there are 34
million FH cases worldwide [1, 3] and that less than
1 % of potential patients with FH have been identified
in most countries [3].* Correspondence: s.watterson@ulster.ac.uk
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likelihood of CHD onset prior to age 55 (men) and
60 (women). Half of all untreated HeFH men and
15 % of women will die of CHD-induced myocardial
infarction (MI) before these ages [3, 4]. Homozygous
FH (HoFH) is rare with an estimated global preva-
lence of 1/160,000–300,000 [5]. However, when left
untreated, patients with HoFH can succumb to MI
as teenagers [4] with one reported case of a 4 year
old child dying from CHD-induced MI [6].
In certain populations, the frequency of heterozy-
gous FH may be markedly higher than 1 in 200.
When a population is descended from a small
number of colonizing ancestors amongst whom the
prevalence of the condition was high, a founder effect
occurs. Such founder effects are thought to be
responsible for the prevalence of FH associated vari-
ants amongst Finns, Icelanders, Christian Lebanese,
Tunisians, Gujarati South African Indians, Ashkenaziticle is distributed under the terms of the Creative Commons Attribution 4.0
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that is as high as 1 in 67 for Ashkenazi Jews. Homozygous
FH (HoFH) has been recorded as ten-fold higher in
founder populations, principally due to consanguineous
marriages [8].
Hydroxymethylglutaryl coenzyme A (HMGCoA) re-
ductase inhibitors (statins) [9–11] are now the first
line treatment for HeFH and HoFH. Prior to their
emergence, mortality rates resulting from CHD in FH
patients were nearly 100-fold greater in young adults
aged 20–39, and approximately 4-fold greater in pa-
tients aged 40–59 than background [12]. However,
there exists potential for improvement in the current
detection and management of FH. Of those diag-
nosed, it has been shown that currently only 10–25 %
receive appropriate therapy [13].
Here, we review the genetics of FH and the ef-
ficacy of FH screening programmes. We suggest that
the expansion of screening programmes has the
potential to contribute significant economic and
social benefit.Fig. 1 The LDLR pathway. The LDL receptor (LDLR), part of a LDLR/clathrin
them (1) [26]. The receptor-ligand complex dissociate and LDLR is either re
regulate the transcription of LDLR (4). PCSK9 is endogenously secreted from
PCSK9 can exogenously bind to LDLR (6). Once internalised to the hepatoc
cent evidence suggests that PCSK9 can bind to LDL via ApoB in free circulReview
The genetic basis of FH
Elevated cholesterol was first demonstrated as a major
risk factor for CHD in 1961 [14]. Lipoproteins were
subsequently identified as a factor in atherosclerosis [15]
and they were classified into the following cholesterol-
carrying types in order of increasing density: chylomi-
crons, very-low-density lipoprotein (VLDL), Low Density
Lipoprotein (LDL), intermediate-density lipoprotein
(IDL) and high-density lipoprotein (HDL). The regula-
tion of cholesterol via the LDL-receptor (LDLR) pathway
featuring receptor-mediated endocytosis was recognised
as critical to atherosclerosis [16] and this facilitated the
identification of genetic defects that cause malfunction
of the LDL receptor as a major risk factor [17].
The majority of FH cases are caused by mutations in the
LDLR gene, resulting in defective synthesis, assembly,
transport, recycling or vesicle formation (Fig. 1). Mutations
in the LDLR gene cause FH in 79 % of cases.
Apolipoprotein B (ApoB) helps the LDL-receptor bind LDL
and mutations in ApoB account for ~5 % of FH cases./LDLRAP1(ARH) vesicle, binds to the ApoB in LDL particles, internalsing
cycled (2a and 3a) or degraded (2b and 3b). Residual cholesterol levels
the Golgi apparatus where it binds to LDLR (5) [93]. Alternatively,
yte, PCSK9 directs bound LDLR to the lysosome for degradation. Re-
ation (7) [94]
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degrades the LDL-receptor and gain of function mutations
in PCSK9 account for <1 % of FH cases [18]. A very rare
recessive form of FH is caused by mutations in low-density
lipoprotein receptor adaptor protein 1 (LDLRAP1). The
remaining 15 % of FH cases are either polygenic or are
driven by monogenic mutations whose prevalence is not
yet determined [18]. The latter include mutations in APOE
[19], APOB [20], SREBP2 [21] and STAP1 [22].
The FH variant database maintained as part of the
Leiden Open Variation Database (LOVD) stores the num-
ber of sequence variants for LDLR, PCSK9, and LDLRAP1
[23–25]. Our discussion of the genetic basis of FH describes
data from the current release of the LOVD. However, the
number of reported variants and our understanding of their
role is likely to develop as a result of future studies.
LDLR
To date research has uncovered a large number of muta-
tions in the LDL-receptor protein associated with FH.Fig. 2 LDLR gene. a. Location of the LDLR gene, the short (p) arm of chrom
lone exons or sets of exons that encode the various domains of the LDLR
of the LDLR gene. The phenotypic presentation of these sequence mutatio
[26]. Data extracted from [23–25]The LOVD FH variant database describes 1741 muta-
tions (retrieved 3rd July 2015). Of these, 1295 are under-
stood to be unique variants, with 1064 predicted to be
pathogenic, 143 predicted to be non-pathogenic, and 88
of unknown significance (personal communication, Dr.
Sarah Leigh, 13 July 2015). Mutations can yield FH
through a range of mechanisms. These include affecting
splicing of the pre-messenger RNA (pre-mRNA), alter-
ing the promoter region that affects gene transcription,
through single amino acid substitutions, creating prema-
ture stop codons and introducing large rearrangements.
These mutations affect the structure and function of the
LDL-receptor and range across the entirety of the LDLR
gene (Fig. 2), with nearly all amino acid substitutions
identified as having deleterious effects. When the
mutation occurs as a large rearrangement, or in cysteine-
rich repeats either as substitutions or premature stop
codons, it produces an entirely non-functional protein
[26]. Defects in a splice junction beside an exon may or
may not effect splicing.osome 19 at position 13.2. b. Numbered vertical bars represent exons,
protein. c. Currently 1,741 mutations have been identified in the exons
ns are discussed in detail elsewhere [29, 30]. Partially adapted from
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ApoB variants are principally located on one exon, num-
ber 26 (Fig. 3). Patients with Familial Ligand-Defective
Apolipoprotein B may have a milder form of presentation
of FH than that caused by LDLR mutations [27].
PCSK9
Missense mutations in PCSK9 that cause a gain-of-function
lead to a rare form of FH [28]. Loss-of-function in certain
ethnic populations has been shown to result in lower LDL-
C levels and protect against CHD [28]. Figure 4 shows both
gain-of-function and loss-of-function variants along with
variants of unknown significance [23–25, 29, 30].
PCSK9 inhibition/repression has emerged as an
important objective in clinical trials where PCSK9
inhibitors have demonstrated significant cholesterol
lowering efficacy [31].
LDLRAP1
LDLRAP1 mutations show a recessive model of in-
heritance. As such, this rarely-occurring disease is
termed autosomal recessive hypercholesterolaemia
(ARH, OMIM #603813) to differentiate it from theFig. 3 ApoB gene. a. Location of the ApoB gene on the short (p) arm of ch
representing the exons. c. Only 8 disease-associated sequence variants hav
mutational hotspot exon 26. When translated this domain functions as theFH conditions attributable to LDLR, PCSK9, and
ApoB mutations [32]. Figure 5 shows the distribution
of known mutations across LDLRAP1. Exon 2 muta-
tions lead to a phenotype similar to HoFH. Mutations
in exon 6 have been shown to be more receptive to
lipid-lowering therapy [29, 30]. ARH cases generally
have lipid levels between those of HeFH and HoFH
patients and ARH patients tend to be the progeny of
ARH consanguineous marriages [33]. HDL levels are
greater than those of patients with HoFH. Conse-
quently, early-onset CHD is postponed. Unlike HoFH,
no case of a patient under 20 years old with CHD
has been recorded.
Diagnosis
Identification of FH is primarily by clinical diagnosis
with subsequent confirmation by genetic testing where
possible. A family history of premature CHD, a clinical
history of premature CHD, physical examination for
xanthomas and corneal arcus and elevated plasma LDL-
C concentration are all used in diagnosis. These charac-
teristics have been used to develop the most widely used
clinical criteria to aid diagnosis: the Dutch Lipid Clinicromosome 2 between positions 24 and 23. b. Numbered vertical bars
e been found to occur in ApoB, and the majority of these are at the
region for LDLR binding. Data extracted from [23–25]
Fig. 4 PCSK9 gene. a. Location of the PCSK9 gene on the short (p) arm of chromosome 1 at position 32.3. b. The numbered vertical bars
represent exons. c. There are 163 mutations seen in the PCSK9 gene, some causing gain-of–function and some causing loss-of-function.
Data extracted from [23–25]
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Genetic analysis is suggested if the DLCN score is >5.
Two other widely used and clinically proven diagnostic
tools are the Simon Broome Register (SBR) criteria used
in the UK and shown in Table 2 [35] and the Make Early
Diagnosis to Prevent Early Death (MEDPED) criteria
used in the USA and shown in Table 3 [36]. No inter-
national standard currently exists. SBR and DLCN are
similar in their choice of criteria, but SBR accepts the
presence of a DNA mutation as a definitive confirmation
of FH, whereas DLCN needs additional criteria for
definite FH diagnosis. For patients with a diagnosis of
‘definite’ FH by SBR criteria, a causal mutation can be
found in greater than 80 % of cases [7, 37]. Each
system adopts different cholesterol cut-offs for con-
cluding premature CHD. The MEDPED criteria rely
on age-specific and family relative-specific total chol-
esterol (TC) only. Although easy to use, MEDPED
does not incorporate clinical characteristics or identi-
fied FH gene mutations. Their relative merits have
been explored in comparative studies [38] and, using a
genetic diagnosis as the comparator, SBR criteria havedemonstrated a sensitivity of 34 % and a specificity of
89 % for FH diagnosis [39].
Recent research has developed a FH prognostic
model, Familial Hypercholesterolaemia Case Ascer-
tainment Tool (FAMCAT), composed of nine clinical
factors, to enhance FH case identification in primary
care [40]. The FAMCAT model may be more sensitive
than DLCN, SBR or MEDPED [40] and is based on
SBR criteria including family history details such as
MI, FH, and raised cholesterol. However, its clinical
utility has yet to be assessed.
There is emerging evidence that a large proportion of
patients with a clinical diagnosis of FH in whom a causative
mutation cannot be detected may have polygenic hyper-
cholesterolaemia, i.e. an accumulation of mutations, each of
which individually has a small LDL raising effect but which
together result in the level of LDL cholesterol elevation
typically found in FH patients [41]. By using a gene loading
score based on 12 common LDL-raising Single Nucleotide
Polymorphisms (SNPs), it has been shown that mutation
negative FH cases demonstrate a significantly higher LDL
gene loading score than in control subjects [41].
Fig. 5 LDLRAP1 gene. a. Location of the LDLRAP1 gene on the short (p) arm of chromosome 1 at position 36.11. b. Numbered vertical bars
represent the exons. c. 39 mutations seen in LDLRAP1 and each exon mutation produces various phenotypic effects, for example, a mutation in
exon 6 will be more responsive to lipid-lowering therapeutics [29, 30]. Data extracted from [23–25]. Partially adapted from [26]
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mias such as Familial Combined Hyperlipidaemia (FCHL)
and polygenic hypercholesterolaemia with increased Lp(a),
both of which may be associated with increased vascular
risk and may present with a clinical phenotype suggestive
of FH. FCHL is a condition in which the patient has serum
cholesterol and/or triglyceride concentration exceeding
the 90th percentile of the age and sex matched healthy
population and raised serum cholesterol and/or triglycer-
ide in at least one first degree relative [42]. FCHL is con-
sidered to be the most common inherited lipid disorder
and an important risk factor for vascular disease with a
prevalence of 10–20 % amongst survivors of myocardial
infarction. Although FCHL shows autosomal dominant
inheritance with low penetration, the causative genes
remain unclear. Associated with polygenic hypercholester-
olaemia, Lp(a) is a circulating lipoprotein consisting of an
LDL particle covalently bound to apolipoprotein(a). Circu-
lating serum Lp(a) concentration is determined largely byvariation in the apolipoprotein(a) gene and elevated Lp(a) is
an independent risk factor for vascular disease [43]. Pa-
tients with polygenic hypercholesterolaemia and increased
Lp(a) may therefore be clinically misdiagnosed as FH cases.
In order to diagnose FH, secondary causes of hyperlip-
idaemia must be ruled out by excluding cholestatic liver
disease, hypothyroidism, significant proteinuria, diabetes
mellitus and excess alcohol [3].
Treatment
The National Institute for Health and Care Excellence
(NICE) in the UK recommends FH cases should
target a reduction in LDL-C levels of over 50 % from
baseline (i.e. LDL-C levels before therapy) [44],
whereas the European Society of Cardiology/European
Atherosclerosis Society (EAS) recommends that the
target level for acceptable LDL-C is <1.8 mmol/l in
HeFH patients with confirmed CHD, and <2.5 mmol/l
in HeFH patients without confirmed CHD [3].
Table 1 DLCN Diagnostic Criteria for FH
Group 1: Family History Points
i. First-degree relative with premature CHDa 1
ii. First-degree relative with LDL-C > 95th percentile
by age, gender for country
1
iii. First-degree relative with tendinous xanthomata
and/or arcus cornealis
2
iv. Children under 18 years with LDL-C > 95th
percentile by age, gender for country
2
Group 2: Clinical History Points
i. Premature CHD 2
ii. Premature cerebrovascular or peripheral vascular disease 1
Group 3: Physical Examination Points
i. Tendinous xanthomata 6
ii. Arcus cornealis prior to 45 years 4
Group 4: LDL-C Levels Points
i. LDL-C > 8.5 mmol/l (~330 mg/dl) 8
ii. LDL-C 6.5-8.4 mmol/l (~250-329 mg/dl) 5
iii. LDL-C 5.0-6.4 mmol/l (~190-249 mg/dl) 3
iv. LDL-C 4.0-4.9 mmol/l (~155-189 mg/dl) 1
Group 5: DNA Analysis Points
i. Causative mutation in the LDLR, ApoB or PCSK9 gene 8
Total Score: -
Definite FH > 8 points
Probable FH: 6–8 points
Possible FH: 3–5 points
Unlikely FH: 0–2 points
Genetic Testing For: -
i. Patients with a score > 5 points
ii. Patients with an obvious diagnosis of xanthomata with
high cholesterol and a CHD family history
Causative Mutation Found: -
Genetic testing for all first degree relatives
aCHD Before age 55 (men), 60 (women)
Table 2 Simon Broome Register Diagnostic Criteria
A diagnosis of explicit FH requires either (1), (2) or (3)
1 i. Cholesterol higher than 7.5 mmol/L or LDL-cholesterol above 4.
ii. Tendon xanthomas in patient or a 1st degree relative (parent, s
2 i. Cholesterol higher than 6.7 mmol/L or LDL-cholesterol above 4.
ii. Tendon xanthomas in patient or a 1st degree relative (parent, s
3 i. DNA based evidence of a functional LDLR, PCSK9 and APOB mu
A diagnosis of probable FH requires either (1), (2) or (3)
1 i. Cholesterol higher than 7.5 mmol/L or LDL-cholesterol above 4.
ii. Family History of myocardial infarction (MI) before 50 years of a
2 i. Cholesterol higher than 6.7 mmol/L or LDL-cholesterol above 4.
ii. Family History of myocardial infarction (MI) before 50 years of a
3 i. A family history of raised total cholesterol - higher than 7.5 mm
or sibling aged under 16 years
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HeFH patients treated with either simvastatin or atorva-
statin had a 76 % overall risk reduction in CHD and no
increased risk of adverse effects associated with statin
therapy, including increased plasma liver enzyme activ-
ity, myalgia and, less commonly, rhabdomyolysis and
myopathy [4]. However, high-intensity statin therapy
may be associated with an increased risk of developing
type 2 diabetes mellitus [46].
Almost 80 % of FH patients prescribed statin therapy
do not attain the EAS recommended LDL-C levels [47].
In a small number of FH cases it has been suggested that
this is due to statin resistance connected to polymor-
phisms in a number of genes, although this picture is
currently unclear [48]. Alternative hypotheses include
non-compliance due to adverse side-effects or patient
choice [49].
Ezetimbe, a cholesterol lowering drug that blocks chol-
esterol absorption in the small intestine may be used in
combination with statin therapy in patients who are not
achieving lipid targets on statin monotherapy or in pa-
tients who are intolerant of statins. Other therapeutic
agents include bile acid sequestrants, mipomersen (an
inhibitor of apolipoprotein B-100 synthesis), lomitapide
(a microsomal triglyceride transfer protein inhibitor),
PCSK9 inhibitors [4], Fibrates [50] and Niacin [51],
some of which have been demonstrated in combination
with statins [52, 53]. In the case of HoFH, high-intensity
statin treatment and LDL apheresis can be used [4].
It has been estimated that 96–98 % of CHD deaths in
FH patients aged less than 40 years could potentially be
averted with just statin therapy [54].
For children diagnosed with FH, lifestyle and diet are
targeted. Many statins are approved for use from the
ages of 8–10, although Atorvastatin has been approved
for use from age 6 [18]. In the UK, NICE recommends
consideration of statin therapy from age 10 years.
Ezetimbe has been approved for use from the age of 109 mmol/L in adult
ibling, child), or in a 2nd degree relative (grand parent, uncle, aunt)
0 mmol/L in a child under 16 years of age
ibling, child), or in a 2nd degree relative (grand parent, uncle, aunt)
tation
9 mmol/L in adult
ge in a 2nd degree relative or below age 60 in a 1st degree relative
0 mmol/L in a child under 16 years of age
ge in a 2nd degree relative or below age 60 in a 1st degree relative
ol/L in adult 1st or 2nd degree relative or higher than 6.7 mmol/L in a child
Table 3 The US (MEDPED) Diagnostic Criteria for FH. FH is
diagnosed if total cholesterol (TC) levels exceed the threshold
stated [95]
Age
(years)
First Degree
relative with
FH (TC, mmol/L)
Second Degree
relative with FH
(TC, mmol/L)
Third Degree
relative with
FH (TC, mmol/L)
General
Population
(TC, mmol/L)
<20 5.7 5.9 6.2 7
20-29 6.2 6.5 6.7 7.5
30-39 7 7.2 7.5 8.8
≥40 7.5 7.8 8 9.3
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been approved for use from age 10 in the USA. Screen-
ing is recommended from the age of 5 although this can
be complicated by issues around parental consent [18].
Screening
FH has no formal disease classification under current
WHO disease classifications [3, 55]. Cascade screening
(CS), whereby family members are traced from an estab-
lished FH index case, is more cost effective than any
other screening strategy currently available [56] and is
recommended in NICE guidelines [44]. Approximately
half of the first degree relatives of an index case will be
found to have the FH mutation [57]. NICE recommends
against using SBR criteria for case detection of relatives
of an index case as this results in under-diagnosis [44]
and instead to use genetic testing (where the causa-
tive mutation in the index case has been identified)
or to use age- and gender-specific LDL-C concentration
where a genotypic result is not available in the index
case [58].
At the introduction of CS in the Netherlands, 2039
relatives of 237 index cases were found to have FH with
39 % already taking treatment. A year later this had risen
to 93 % [59]. To date, approximately 23,000 FH cases
have been determined in the Netherlands by CS alone
[17]. CS has also proven to be effective in Australia and
Brazil, where each index case typically yields a further 2
cases [60, 61]. However, in the UK, it has proven less
effective, yielding between 0.4 and 0.7 new cases per FH
index case [57, 62, 63]. CS has still demonstrated its
clinical utility in the UK [64], decreasing the age of
FH diagnosis and increasing the number of people
with FH on statin therapy [45].
It has been shown that even with systematic CS
through to 3rd degree relatives, in a ‘best case’ detection
scenario of 8.6 relatives per index case as in the
Netherlands model [59], 17 % of FH cases must be iden-
tified as index cases in order to achieve a detection rate
of 80 % of putative FH cases after introducing CS [65].
An alternative to CS is universal screening (UScr) in
which a population is systematically screened. This has
not yet been applied to FH, but could be undertaken bycholesterol measurement or genotyping in childhood.
Genotyping might be more effective for populations in
which founder effects occur with a restricted number of
prevalent mutations. UScr has been a great public health
triumph for detecting and treating disorders such as
phenylketonuria (PKU), medium-chain acyl-CoA de-
hydrogenase deficiency (MCAD), cystic fibrosis (CF)
[66] and cervical cancer [67]. The newborn screening
programmes implemented for CF have shown direct
benefits such as preventing malnutrition [68] and may
lead to indirect benefits such as informing parental
reproductive choices, reducing parental stress and facili-
tating clinical trial recruitment [69]. Such advantages
have led some to advocate genome wide analyses from a
single sample although there are significant ethical and
regulatory considerations to doing so [70].
International guidelines advocate targeted screening
for the identification of new FH index cases [71] in
which screening can be directed at specific patient
groups likely to show a high prevalence of FH such
as those post acute coronary syndrome. A study
based around an Australian coronary care unit dem-
onstrated that the prevalence of possible/definite FH
(as defined by DLCN criteria) was as high as 14.3 %
in patients below the age of 60 with a current or
prior history of coronary artery disease [72]. Such
targeted screening is an effective strategy for identifying
new FH index cases.
It has been suggested that new FH index cases could
be identified systematically from electronic health re-
cords [73, 74], but a preliminary study yielded disap-
pointing results with only 2 new definite FH index cases
identified from a population of 12,100 [75]. However, a
strategy that would likely yield a higher FH detection
rate is Reverse Cascade Screening (RCS) [76]. This com-
bines elements of UScr and CS and involves screening
an infant’s total cholesterol (TC) when they receive
vaccinations at 15 months of age. Following the identifi-
cation of elevated cholesterol (here defined as 1.5 times
the median for age), DNA analysis can be utilised to
identify relevant mutations and, should they exist, the
parents and grandparents would be tested subsequently.
It has been suggested that by running this programme
for one generation, most, if not all, FH cases would be
detected and registered [65].
Screening has conventionally been undertaken by
array or PCR amplification. Sanger sequencing has
demonstrated its value, but has proven prohibitively
expensive. However, Next Generation Sequencing (NGS)
with its ability to undertake parallel sequencing rela-
tively quickly, has shown great promise [77]. NGS has
demonstrated high levels of specificity and sensitivity
[78] in particular when combined with clinical criteria
[79, 80].
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without controversy. As FH is only an indicator for likely
elevated LDL-C and a proportion of elevated LDL-C
cases are negative for the canonical variants, it has been
argued that screening should focus on phenotype rather
than genotype, both for the identification of index cases
and in cascade screening, and that a focus on genetic
screening can offer false reassurances to variant-negative
patients who might still be at risk [81, 82]. The guide-
lines for screening of FH, provided by the National Lipid
Association (USA), still focus principally on phenotypic
diagnosis [83].
Economics
Detection and treatment of FH leads to significant
savings in healthcare costs [56]. In the UK, it is esti-
mated that the identification and optimal treatment of
all FH cases would save the NHS £380 million over a
55 year period, or £6.9 million/year [84]. When extrapo-
lated to the EU, the savings would yield about €86
million per year [18]. NICE guidelines estimate that CS
leads to an incremental cost effectiveness ratio (ICER) of
£2,700 per quality adjusted life year (QALY). This inter-
vention is considerably less expensive than the £20,000
to £30,000 per QALY ceiling that NICE defines as cost-
effective [85]. Furthermore, the cost of FH testing is
likely to drop by as much as four-fold with the introduc-
tion of next-generation sequencing [86] improving the
cost effectiveness further. It has been estimated that CS
and high-intensity statin therapy would lead to 101
fewer deaths/1000 FH patients by CHD [84].
Discussion
UScr as a general population disease identification strat-
egy has pitfalls in terms of cost and the role of unknown
causative variants. However as sequencing costs con-
tinue to drop, it is likely that new mechanisms of action
will be uncovered and doctors can protect the patient
from the irresolution in the genomic data [87].
Several authors propose that the ideal screening
scenario is the integration of CS and UScr strategies
[2, 88]. Others posit that as the costs of disease
management increases, while the cost of diagnostics
decreases, UScr will become more cost-effective and
attractive, rendering CS less attractive [89]. The hybrid
proposal of RCS [76] may be more cost-effective than
UScr and become more so if DNA sequencing continues
to outpace Moore’s Law in terms of better, cheaper, faster
performance [90, 91].
Early recognition of a child with FH, coupled with ther-
apy from a young age, will impede, if not arrest, the onset
of atherosclerosis [18]. UScr is already used for conditions
such as phenylketonuria, which has a prevalence of 1 per
10,000, so the societal barriers to UScr should be lowerfor diseases such as FH where it has been demonstrated
that testing and treating is clearly beneficial [89].
In the Netherlands, children with FH who have received
counselling as part of their early intervention therapy have
not taken up smoking, a lifestyle risk factor, in 100 % of
cases. Additionally, these children have been shown to
cope effectively with their diagnosis [18, 92].Conclusion
Familial Hypercholesterolaemia is a significant risk factor
for cardiovascular disease, the leading cause of death
globally. Familial Hypercholesterolaemia is an autosomal,
dominant genetic disorder predominantly associated with
pathogenic variants in the genes LDLR, ApoB, LDLRAP1
and gain of function variants in PCSK9. Screening typic-
ally occurs using the Dutch Lipid Clinic Network, the Si-
mon Broome Register or the Make Early Diagnosis to
Prevent Early Death (MEDPED) criteria. Typically, a diag-
nosed case forms an index case from which a cascade
screen is undertaken within the same family to identify as
many new cases as possible. However, alternative screening
programmes include systematic screens across a population
(universal screening) and hybrid schemes in which cascade
screening is applied to systematically screened subpopula-
tions (reverse cascade screening). Cost-effectiveness is
dependent on the scheme. Cascade screening in its typical
form is highly cost-effective, although more systematic pro-
grammes may become more competitive if genome se-
quencing costs continue to fall.
The ability to identify FH patients at the earliest
opportunity is both economically and socially beneficial
with implications for mortality and morbidity.
Whichever screening strategy is optimal, studies of
screening programmes will not only address FH as one of
the world’s most prevalent and treatable inherited diseases,
but have the potential to contribute to broader studies of
hereditary diseases with similar traits.
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